Kinoxis Therapeutics
A biotechnology startup developing new therapeutics to address the escalating demand for effective treatments for substance use disorders and social dysfunction in neurological and psychiatric disorders.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
* | N/A | AUD2.5m | Grant |
| Total Funding | 000k | ||
Related Content
Kinoxis Therapeutics is a pioneering biopharmaceutical company based in Melbourne, Australia, specializing in the development of therapeutic compounds aimed at enhancing social functioning by targeting specific pathways in the brain. The company primarily focuses on the oxytocin receptor, utilizing selective partial agonism and positive allosteric modulation to restore normal social behavior. Kinoxis serves patients suffering from social dysfunction and substance abuse disorders, operating within the behavioral neuroscience and psychiatric treatment markets. The business model revolves around extensive research and development, backed by significant funding from venture funds like Uniseed and grants from institutions such as the US National Institutes of Health National Institute on Drug Abuse. Revenue is generated through partnerships, licensing agreements, and the commercialization of its therapeutic compounds.
Keywords: biopharmaceutical, oxytocin receptor, social dysfunction, substance abuse, psychiatric treatment, behavioral neuroscience, therapeutic compounds, venture funding, medicinal chemistry, brain pathways.